Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Mehnert W, Mder K
Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history
Contact Us GLP-1 agonists are powerful tools for weight management, but they dont work alone the right support is essential
This is a serious problem for several reasons: Muscle loss slows your resting metabolic rate, making it harder to keep weight off after stopping the medication Reduced muscle mass increases the risk of falls, fractures, and loss of physical function particularly in older adults The skinny fat phenomenon normal BMI but high body fat percentage is a real outcome of poorly managed GLP-1 use The solution is not to avoid GLP-1 medications
Products ranging from purported medications and supplements, to devices that claim to be blood glucose monitors are also carrying the logos of Obesity Canada and Health Canada
